Literature DB >> 30291672

Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C-Related Liver Disease.

Giorgio A Roccaro1, Robert Mitrani2, Wei-Ting Hwang3, Kimberly A Forde2,3, K Rajender Reddy2.   

Abstract

Posttransplant diabetes mellitus (PTDM), an increasingly recognized complication of solid organ transplantation, is associated with increased morbidity and mortality following liver transplantation (LT). Hepatitis C virus (HCV) infection is a consistent and modifiable risk factor for PTDM. Prior studies have demonstrated improvement in glucose metabolism following sustained virological response (SVR). However, the effect of SVR on the incidence of PTDM has not been previously investigated in a large cohort of LT recipients. We performed a single-center retrospective cohort study of LT recipients with HCV from January 1, 2010 to June 30, 2015 to compare the risk of sustained posttransplant diabetes mellitus (s-PTDM) prior to and following SVR. SVR was treated as a discrete time varying exposure. The s-PTDM was defined as de novo diabetes mellitus following LT of a >6-month duration. Univariate and multivariate Cox proportional hazards models were used to compare crude and adjusted time to s-PTDM prior to and following SVR. There were 256 eligible LT recipients analyzed. Median follow-up was 41.2 months. Overall, 31 (12.1%) and 178 (69.5%) patients achieved SVR prior to LT and following LT, respectively. During follow-up, 71 (27.7%) patients developed s-PTDM. The incidence of s-PTDM was greatest in the first year after LT. After adjustment for potential confounders, SVR was associated with a significantly reduced risk of s-PTDM (HR, 0.40; P = 0.048). In conclusion, eradication of HCV is independently associated with a reduced incidence of s-PTDM. This benefit appears to be most influenced by pre-LT SVR and persists throughout the post-LT period. Given the association between PTDM and posttransplant morbidity and mortality, these data provide another motivator for pre-LT or early post-LT treatment of HCV.
Copyright © 2018 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30291672      PMCID: PMC6279473          DOI: 10.1002/lt.25351

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  21 in total

1.  Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.

Authors:  David Goldberg; Ivo C Ditah; Kia Saeian; Mona Lalehzari; Andrew Aronsohn; Emmanuel C Gorospe; Michael Charlton
Journal:  Gastroenterology       Date:  2017-01-11       Impact factor: 22.682

2.  Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Authors:  Varun Saxena; Vandana Khungar; Elizabeth C Verna; Josh Levitsky; Robert S Brown; Mohamed A Hassan; Mark S Sulkowski; Jacqueline G O'Leary; Farrukh Koraishy; Joseph S Galati; Alexander A Kuo; Monika Vainorius; Lucy Akushevich; David R Nelson; Michael W Fried; Norah Terrault; K Rajender Reddy
Journal:  Hepatology       Date:  2017-09-04       Impact factor: 17.425

3.  Negative impact of new-onset diabetes mellitus on patient and graft survival after liver transplantation: Long-term follow up.

Authors:  Jang I Moon; Ralph Barbeito; Raquel N Faradji; Jeffrey J Gaynor; Andreas G Tzakis
Journal:  Transplantation       Date:  2006-12-27       Impact factor: 4.939

4.  Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study.

Authors:  Faouzi Saliba; Mohamed Lakehal; Georges-Philippe Pageaux; Bruno Roche; Claire Vanlemmens; Christophe Duvoux; Jérôme Dumortier; Ephrem Salamé; Yvon Calmus; Didier Maugendre
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

5.  Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.

Authors:  C S Wang; H H Ko; E M Yoshida; C A Marra; K Richardson
Journal:  Am J Transplant       Date:  2006-07       Impact factor: 8.086

6.  Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality.

Authors:  S Baid; A B Cosimi; M L Farrell; D A Schoenfeld; S Feng; R T Chung; N Tolkoff-Rubin; M Pascual
Journal:  Transplantation       Date:  2001-09-27       Impact factor: 4.939

7.  OPTN/SRTR 2015 Annual Data Report: Liver.

Authors:  W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2017-01       Impact factor: 8.086

8.  Hepatitis C virus infection and incident type 2 diabetes.

Authors:  Shruti H Mehta; Frederick L Brancati; Steffanie A Strathdee; James S Pankow; Dale Netski; Josef Coresh; Moyses Szklo; David L Thomas
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

9.  Incidence and risk factors for new-onset diabetes in living-donor liver transplant recipients.

Authors:  Masaki Honda; Katsuhiro Asonuma; Shintaro Hayashida; Hiroko Suda; Yuki Ohya; Kwang-Jong Lee; Hidekazu Yamamoto; Takayuki Takeichi; Yukihiro Inomata
Journal:  Clin Transplant       Date:  2013-03-07       Impact factor: 2.863

10.  Diagnosis and classification of diabetes mellitus.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

View more
  1 in total

Review 1.  Post-transplant diabetes mellitus.

Authors:  Tahseen A Chowdhury
Journal:  Clin Med (Lond)       Date:  2019-09       Impact factor: 5.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.